Evidence map›Paper›PMID 40522060›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Non-amnestic initial symptoms may be less prevalent in African American than White participants with Alzheimer's and mixed Lewy body and Alzheimer's pathology.

Quintasha Beamon, Audrey Zhu, James B Leverenz, Jagan A Pillai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Quintasha BeamonLou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
Audrey ZhuLou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
James B LeverenzLou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
Jagan A PillaiLou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUI, HELENA CHANG · 1985 to 2019
$41.0M
VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J. · 1985 to 2019
$37.6M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI YASSA, MICHAEL A · 2000 to 2019
$37.0M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
ADCs P30 AG062421-01ADCs P30 AG062422-01ADCs P30 AG062428-01ADCs P30 AG062429-01ADCs P30 AG062715-01Annabelle FoundationIversen Family Endowed Chair in Alzheimer's Disease Research DoD W81XWH-21-PRARP-CSRAIversen Family Endowed Chair in Alzheimer's Disease Research R01 AG078763-01Iversen Family Endowed Chair in Alzheimer's Disease Research R21AG074287-01A1Keep Memory Alive FoundationNIA NIH HHS P30 AG008017NIA NIH HHS P30 AG008051NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG012300NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG028383NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062428NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072959NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005138NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG023501NIA NIH HHS P50 AG025688NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG078763NIA NIH HHS R21 AG074287NIA NIH HHS U01 AG016976(NIH) 1P30 AG062428(NIH) 1P30 AG072959NIH HHSNINDS NIH HHS U01 NS100610
6 · The paper itself

Abstract

introductionKnowing the relationship between initial clinical symptoms and rate of clinical decline by race is important in dementia care.

methodsA retrospective longitudinal cohort study of 2887 participants with autopsy confirmed AD pathology (ADP), and mixed ADP with Lewy body pathology (AD-LBP) in the National Alzheimer's Coordinating Center database. Two-sample t-tests and Fisher's exact tests were used to evaluate outcomes.

resultsAfrican American participants (AAs) were less likely to have initial non-amnestic symptoms than White participants (6.5% vs 23% p < 0.001). AAs showed a faster rate of clinical decline on the Clinical Dementia Rating-Sum of Boxes than Whites in the amnestic group (0.30 points per year, 95% confidence interval [CI]: 0.04 to 0.55; p = 0.023). When accounting for biological and social-medical factors, the difference between the races were not significant (0.16, 95% CI: -0.10 to 0.42; p = 0.22). DISCUSSION: Larger diverse cohorts are necessary to robustly evaluate interaction between race and clinical factors in determining dementia outcomes. HIGHLIGHTS: African American participants were less likely to have initial non-amnestic symptoms than White participants with Alzheimer's disease and mixed Alzheimer's and Lewy body neuropathology. African American participants with initial amnestic symptoms in the National Alzheimer's Coordinating Center cohort also experienced a faster rate of cognitive and functional decline. Interaction between race, clinical symptoms, and neuropathology in diverse populations is an important consideration in clinical trial design.

Indexed as

Alzheimer DiseaseBlack or African AmericanLewy Body DiseaseWhiteAgedAged, 80 and overFemaleHumansLongitudinal StudiesMalePrevalenceRetrospective StudiesAfrican AmericanAlzheimer'sinitial cognitive symptomLewy bodymixed dementianeuropathologyracerate of progressionWhite

Identifiers

PMID40522060
PMCPMC12168484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.